Automated bulk classification of glaucoma severity and progression using perimetry results

• by Nancy Wang, Arun J. Thirunavukarasu, Hita Patel, Rosia Li, Tasneem Z. Khatib

• September 12, 2026

The retinal nerve fibre layer thickness slope: a localised biomarker of the structure–function relationship in early glaucoma

• by Stefan Steiner, Florian Frommlet, Florian Schwarzhans, Georg Fischer, Maximilian Pirrung, Michael Pircher, Christoph Hitzenberger, Clemens Vass

• July 1, 2026

Editorial: The role of light in myopia

• by Natali Gutierrez-Rodriguez, Valentina Bilbao-Malavé, Manuel Garza-León, Sandra Johana Ganzón-Parra, Jorge González-Zamora, Sergio Recalde Maestre

• September 2, 2026

Perspectives on Medicare’s Proposed iDose TR Coverage Policy

In May 2026, 5 Medicare Administrative Contractors released proposed Local Coverage Determinations (LCDs) addressing Medicare reimbursement for anterior-segment intraocular nonbiodegradable drug-eluting systems, a category that currently includes only the travoprost intracameral implant iDose TR (Glaukos). Many glaucoma specialists believe the proposed LCDs do not reflect contemporary glaucoma practice or the clinical rationale underlying sustained drug-delivery therapies. Glaucoma Physician spoke with several leading surgeons about the proposed LCDs, the reasons for their concerns, and the changes they believe would better reflect contemporary glaucoma practice.

• by Steven R. Sarkisian, Jr., MD, Inder Paul Singh, MD, Savak “Sev” Teymoorian, MD, MBA, Manjool Shah, MD, Christine Funke, MD, Philip S. Garza, MD, MSc

• September 1, 2026

• 10 min